Michelle Kimple, phd
Assistant Professor, Medicine (Endocrinology, Diabetes & Metabolism)
4148 UW Medical Foundation Centennial Building
1685 Highland Ave
Dr. Kimple leads a multi-level research team whose focus is on understanding how the beta-cells of the pancreas respond to nutrient and hormonal stimulation to affect biological changes. Her group is especially interested in elucidating how dysfunctional G protein-coupled receptor signaling pathways contribute to the pathogenesis of type 1 and type 2 diabetes and in translating these insights into new and improved diabetes therapeutics. Dr. Kimple’s research has been funded almost continuously from her PhD onwards by the National Institutes of Health and the Juvenile Diabetes Research Foundation, among other agencies. Her work has been featured in several university press releases and patent applications. Dr. Kimple has been the recipient of several awards, including a Preparing Future Faculty Fellowship from Duke University, where she learned the skills necessary to be a successful mentor and teacher while maintaining a top-tier research laboratory.
Honors & Awards
- Mentor, American Society for Pharmacology & Experimental Biology (ASPET) Zannoni Summer Undergraduate Research Fellowship
- Mentor, Hilldale Undergraduate/Faculty Research Fellowship
- Best Poster Award, Drug Development Category, American Society of Biochemistry and Molecular Biology, Experimental Biology 2012
- Mentored Research Scientist Development Award, NIH/NIDDK
- Duke ‘Preparing Future Faculty’ Program Fellowship
Michelle Kimple, PhD, assistant professor, Division of Endocrinology, Department of Medicine, was funded by the American Diabetes Association for her proposal titled “Arachidonic Acid Metabolism and Beta-Cell Dysfunction: Beyond COX-2.” The long-term goal is to fully characterize the PGE2 synthesis and signaling pathways in the normal and diabetic beta-cell, determining steps that become dysfunctional in the diabetic state, and ultimately modulating these steps for preventative and therapeutic purposes.
- Pierre JF, Neuman JC, Brill AL, Brar HK, Thompson MF, Cadena MT, Connors KM, Busch RA, Heneghan AF, Cham CM, Jones EK, Kibbe CR, Davis DB, Groblewski GE, Kudsk KA, Kimple ME. The Gastrin Releasing Peptide Analog, Bombesin, Preserves Exocrine and Endocrine Pancreas Morphology and Function during Parenteral Nutrition. Am J Physiol Gastrointest Liver Physiol. 2015 Jul 16. PubMed PMID: 26185331.
- Busch RA, Heneghan AF, Pierre JF, Neuman JC, Reimer CA, Wang X, Kimple ME, Kudsk KA. Bombesin Preserves Goblet Cell Resistin-like Molecule β During Parenteral Nutrition but Not Other Goblet Cell Products. JPEN J Parenter Enteral Nutr. 2015 May 1. PubMed PMID: 25934045.
- Linnemann AK, Neuman JC, Battiola TJ, Wisinski JA, Kimple ME, Davis DB. Glucagon-Like Peptide-1 Regulates Cholecystokinin Production in β-Cells to Protect From Apoptosis. Mol Endocrinol. 2015 Jul;29(7):978-87. 2015. PubMed Central PMCID: PMC4484781.
- Kimple ME, Neuman JC, Linnemann AK, Casey PJ. Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes. Exp Mol Med. 2014 Jun 20. Review. PubMed Central PMCID: PMC4081554.
- Kimple ME, Keller MP, Rabaglia MR, Pasker RL, Neuman JC, Truchan NA, Brar HK, Attie AD. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion. Diabetes. 2013 Jun;62(6):1904-12. PubMed Central PMCID: PMC3661627.